Nitric Oxide-Mediated Histone Hyperacetylation in Oral Cancer: Target for a Water-Soluble HAT Inhibitor, CTK7A

被引：101

作者：

Arif, Mohammed ^{[1
]}

Vedamurthy, Bhusainahalli M. ^{[1
]}

Choudhari, Ramesh ^{[1
]}

Ostwal, Yogesh B. ^{[1
]}

Mantelingu, Kempegowda ^{[1
]}

Kodaganur, Gopinath S. ^{[2
]}

Kundu, Tapas K. ^{[1
]}

机构：

[1] JNCASR, Mol Biol & Genet Unit, Transcript & Dis Lab, Bangalore 560064, Karnataka, India

[2] Bangalore Inst Oncol, Bangalore 560027, Karnataka, India

来源：

CHEMISTRY & BIOLOGY | 2010年 / 17卷 / 08期

关键词：

GENE-EXPRESSION; ACETYLTRANSFERASE; CHROMATIN; P300; ACETYLATION; CURCUMIN; PROGRESSION; CBP/P300; PHOSPHORYLATION; NUCLEOPHOSMIN;

D O I：

10.1016/j.chembiol.2010.06.014

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Altered histone acetylation is associated with several diseases, including cancer. We report here that, unlike in most cancers, histones are found to be highly hyperacetylated in oral squamous cell carcinoma (OSCC; oral cancer) patient samples. Mechanistically, overexpression, as well as enhanced autoacetylation, of p300 induced by nucleophosmin (NPM1) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) causes the hyperacetylation, which is nitric oxide (NO) signal dependent. Inhibition of the histone acetyltransferase (HAT) activity of p300 by a water-soluble, small molecule inhibitor, Hydrazinocurcumin (CTK7A), substantially reduced the xenografted oral tumor growth in mice. These results, therefore, not only establish an epigenetic target for oral cancer, but also implicate a HAT inhibitor (HATi) as a potential therapeutic molecule.

引用

页码：903 / 913

页数：11

共 48 条

[11] CBP/p300-mediated acetylation of histone H3 on lysine 56 [J].

Das, Chandrima ;

Lucia, M. Scott ;

Hansen, Kirk C. ;

Tyler, Jessica K. .

NATURE, 2009, 459 (7243) :113-U123

[12] The transcriptional coactivator p300 plays a critical role in the hypertrophic and protective pathways induced by phenylephrine in cardiac cells but is specific to the hypertrophic effect of urocortin [J].

Davidson, SM ;

Townsend, PA ;

Carroll, C ;

Yurek-George, A ;

Balasubramanyam, K ;

Kundu, TK ;

Stephanou, A ;

Packham, G ;

Ganesan, A ;

Latchman, DS .

CHEMBIOCHEM, 2005, 6 (01) :162-170

[13]

Debes JD, 2003, CANCER RES, V63, P7638

[14] What has senescence got to do with cancer? [J].

Dimri, GP .

CANCER CELL, 2005, 7 (06) :505-512

[15] Cancer epigenomics: DNA methylomes and histone-modification maps [J].

Esteller, Manel .

NATURE REVIEWS GENETICS, 2007, 8 (04) :286-298

[16] Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer [J].

Fraga, MF ;

Ballestar, E ;

Villar-Garea, A ;

Boix-Chornet, M ;

Espada, J ;

Schotta, G ;

Bonaldi, T ;

Haydon, C ;

Ropero, S ;

Petrie, K ;

Iyer, NG ;

Pérez-Rosado, A ;

Calvo, E ;

Lopez, JA ;

Cano, A ;

Calasanz, MJ ;

Colomer, D ;

Piris, MA ;

Ahn, N ;

Imhof, A ;

Caldas, C ;

Jenuwein, T ;

Esteller, M .

NATURE GENETICS, 2005, 37 (04) :391-400

[17] The role of nitric oxide in tumour progression [J].

Fukumura, Dai ;

Kashiwagi, Satoshi ;

Jain, Rakesh K. .

NATURE REVIEWS CANCER, 2006, 6 (07) :521-534

[18] Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer [J].

Gallo, O ;

Masini, E ;

Morbidelli, L ;

Franchi, A ;

Fini-Storchi, I ;

Vergari, WA ;

Ziche, M .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (08) :587-596

[19] Mutations truncating the EP300 acetylase in human cancers [J].

Gayther, SA ;

Batley, SJ ;

Linger, L ;

Bannister, A ;

Thorpe, K ;

Chin, SF ;

Daigo, Y ;

Russell, P ;

Wilson, A ;

Sowter, HM ;

Delhanty, JDA ;

Ponder, BAJ ;

Kouzarides, T ;

Caldas, C .

NATURE GENETICS, 2000, 24 (03) :300-303

[20] Nucleophosmin and cancer [J].

Grisendi, Silvia ;

Mecucci, Cristina ;

Falini, Brunangelo ;

Pandolfi, Pier Paolo .

NATURE REVIEWS CANCER, 2006, 6 (07) :493-505

← 1 2 3 4 5 →